Amarin Corp Plc (AMRN)

[HDGabor]

Yes, VIVUS / Biopharma looks like the same structure with different conditions:

- based on last 3 payments (0,8 -1,0 – 1,1) Amarin threshold is 10% of (prev.) quarterly revenue
- carried forward without interest
- The payment of any carried forward amount is subject to similarly calculated threshold repayment amounts based on Vascepa revenue levels. (KIWI FYI !!!)
- Except upon a change of control in Amarin, the agreement does not expire until $150 million has been repaid.

‘Pharmakon’s interest for Qsymia to miss its bullish-looking consensus estimates.’ – It’s stupid: longer term – higher risk, lower return %, so Pharmakon’s interest to get the money back a.s.a.p.